Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH119
- Development stage
- Phase 1
- Lead developer
- Wuhan Ruiji Biotechnology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
RH119 is a lyophilized mRNA vaccine developed by Wuhan Ruiji Biotechnology Co., Ltd. and Wuhan Jinyintan Hospital for the prevention of tuberculosis. It is designed to deliver messenger RNA (mRNA) encoding specific antigens of Mycobacterium tuberculosis, prompting the host's cells to produce these antigens and stimulate a protective immune response against the disease.
Beyond the preview
Go deeper on RH119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH119.